GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » ORIC Pharmaceuticals Inc (NAS:ORIC) » Definitions » Insider Ownership

ORIC Pharmaceuticals (ORIC Pharmaceuticals) Insider Ownership : 1.32 % (As of Apr. 27, 2024)


View and export this data going back to 2020. Start your Free Trial

What is ORIC Pharmaceuticals Insider Ownership?

Insider ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, ORIC Pharmaceuticals's insider ownership is 1.32%.

Institutional Ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, ORIC Pharmaceuticals's Institutional Ownership is 27.73%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, ORIC Pharmaceuticals's Float Percentage Of Total Shares Outstanding is 91.96%.


ORIC Pharmaceuticals Insider Ownership Historical Data

The historical data trend for ORIC Pharmaceuticals's Insider Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ORIC Pharmaceuticals Insider Ownership Chart

ORIC Pharmaceuticals Historical Data

The historical data trend for ORIC Pharmaceuticals can be seen below:

2023-06-30 2023-07-31 2023-08-31 2023-09-30 2023-10-31 2023-11-30 2023-12-31 2024-01-31 2024-02-29 2024-03-31
Insider Ownership 1.70 1.67 1.66 1.66 1.66 1.66 1.77 1.44 1.38 1.32

ORIC Pharmaceuticals Insider Ownership Calculation

The percentage of shares that are owned by company insiders relative to the total shares outstanding.


ORIC Pharmaceuticals (ORIC Pharmaceuticals) Business Description

Traded in Other Exchanges
Address
240 E. Grand Avenue, 2nd Floor, South San Francisco, CA, USA, 94080
ORIC Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It has a pipeline of therapies designed to counter resistance mechanisms in cancer by leveraging its expertise within three specific areas: hormone-dependent cancers, precision oncology, and key tumor dependencies. The company has product candidates namely ORIC-944, ORIC-114, and ORIC-533.
Executives
Jacob Chacko director, officer: President and CEO C/O IGNYTA, INC., 11095 FLINTKOTE AVE., SUITE D, SAN DIEGO CA 92121
Pratik S Multani officer: Chief Business Officer C/O FATE THERAPEUTICS, INC., 3535 GENERAL ATOMICS COURT, SUITE 200, SAN DIEGO CA 92121
Dominic Piscitelli officer: Chief Financial Officer C/O ANAPTYSBIO, INC., 10421 PACIFIC CENTER COURT, SUITE 200, SAN DIEGO CA 92121
Pfizer Inc 10 percent owner 66 HUDSON BOULEVARD EAST, NEW YORK NY 10001-2192
Column Group Llc 10 percent owner 1 LETTERMAN DRIVE, BUILDING D, SUITE M-900, SAN FRANCISCO CA 94129
Column Group Ii Gp, Lp 10 percent owner 1700 OWENS STREET, SUITE 500, SAN FRANCISCO CA 94158
Peter Svennilson 10 percent owner 1700 OWENS STREET, SUITE 500, SAN FRANCISCO CA 94158
Column Group Ii, Lp 10 percent owner 1700 OWENS STREET, SUITE 500, SAN FRANCISCO CA 94158
David V Goeddel 10 percent owner C/O COLUMN GROUP LP, 1700 OWENS STREET, SUITE 500, SAN FRANCISCO CA 94158
Angie You director C/O AMUNIX PHARMACEUTICALS, INC., 2 TOWER PLACE, #1100, SOUTH SAN FRANCISCO CA 94080
Richard A. Heyman director 5871 OBERLIN DRIVE, SUITE 150, SAN DIEGO CA 92121
Steven L. Hoerter director C/O DECIPHERA PHARMACEUTICALS, INC., 200 SMITH STREET, WALTHAM MA 02451
Richard H Scheller director C/O GENENTECH INC, 1 DNA WAY MS 49, SOUTH SAN FRANCISCO CA 94080-4990
Orbimed Advisors Llc director 601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022
Carl L Gordon director 601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022

ORIC Pharmaceuticals (ORIC Pharmaceuticals) Headlines

From GuruFocus

ORIC Pharmaceuticals Provides Corporate Update and Highlights Key Upcoming Milestones

By Stock market mentor Stock market mentor 01-09-2023